$KPRX
KIORA PHARMACEUTICALS INC

2022 Q1 Form 10-Q Financial Statement

#000141057822001934 Filed on July 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.665M $1.300M
YoY Change 28.05% 26.23%
% of Gross Profit
Research & Development $707.9K $1.280M
YoY Change -44.7% 36.2%
% of Gross Profit
Depreciation & Amortization $10.77K $10.60K
YoY Change 1.64% 5.99%
% of Gross Profit
Operating Expenses $3.569M $2.010M
YoY Change 77.57% 2.04%
Operating Profit -$3.569M -$2.010M
YoY Change 77.57%
Interest Expense $220.00 $686.00
YoY Change -67.93% -96.57%
% of Operating Profit
Other Income/Expense, Net $4.428K -$436.00
YoY Change -1115.6%
Pretax Income -$3.565M -$2.011M
YoY Change 77.31% 3.11%
Income Tax
% Of Pretax Income
Net Earnings -$3.565M -$2.011M
YoY Change 77.31% 3.11%
Net Earnings / Revenue
Basic Earnings Per Share -$0.27 -$0.27
Diluted Earnings Per Share -$0.27 -$0.27
COMMON SHARES
Basic Shares Outstanding 13.06M 7.358M
Diluted Shares Outstanding 13.06M 7.358M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.067M $6.610M
YoY Change -23.34% 12.42%
Cash & Equivalents $5.067M $6.655M
Short-Term Investments
Other Short-Term Assets $930.4K $233.5K
YoY Change 298.45% -55.1%
Inventory
Prepaid Expenses $930.3K
Receivables
Other Receivables
Total Short-Term Assets $6.550M $6.991M
YoY Change -6.31% 9.41%
LONG-TERM ASSETS
Property, Plant & Equipment $67.30K $327.0K
YoY Change -79.42% 1534.95%
Goodwill
YoY Change
Intangibles $10.76M
YoY Change
Long-Term Investments
YoY Change
Other Assets $53.82K $94.00K
YoY Change -42.74% -27.69%
Total Long-Term Assets $11.09M $13.63M
YoY Change -18.66% 134.99%
TOTAL ASSETS
Total Short-Term Assets $6.550M $6.991M
Total Long-Term Assets $11.09M $13.63M
Total Assets $17.64M $20.62M
YoY Change -14.47% 69.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $302.3K $457.4K
YoY Change -33.91% 185.84%
Accrued Expenses $1.833M $968.3K
YoY Change 89.3% 51.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.521M $1.426M
YoY Change 76.87% 80.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $278.2K
YoY Change -100.0%
Other Long-Term Liabilities $3.055M $5.503M
YoY Change -44.49% 221.81%
Total Long-Term Liabilities $3.857M $5.781M
YoY Change -33.28% 238.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.521M $1.426M
Total Long-Term Liabilities $3.857M $5.781M
Total Liabilities $6.378M $7.936M
YoY Change -19.62% 176.5%
SHAREHOLDERS EQUITY
Retained Earnings -$124.4M
YoY Change
Common Stock $126.6K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.26M $15.99M
YoY Change
Total Liabilities & Shareholders Equity $17.64M $20.62M
YoY Change -14.47% 69.16%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$3.565M -$2.011M
YoY Change 77.31% 3.11%
Depreciation, Depletion And Amortization $10.77K $10.60K
YoY Change 1.64% 5.99%
Cash From Operating Activities -$2.832M -$2.570M
YoY Change 10.21% 7.09%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $58.12K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $6.380K
YoY Change
Cash From Investing Activities $6.375K -$58.12K
YoY Change -110.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $7.989M
YoY Change -100.0% 77.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 8.039M
YoY Change -100.0% 78.64%
NET CHANGE
Cash From Operating Activities -2.832M -2.570M
Cash From Investing Activities 6.375K -58.12K
Cash From Financing Activities 0.000 8.039M
Net Change In Cash -2.787M 5.425M
YoY Change -151.38% 158.32%
FREE CASH FLOW
Cash From Operating Activities -$2.832M -$2.570M
Capital Expenditures $0.00 $58.12K
Free Cash Flow -$2.832M -$2.628M
YoY Change 7.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13058629
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7357899
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12663965
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12663965
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Valuation Technique Extensible List
BusinessCombinationContingentConsiderationLiabilityValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueDiscountedCashFlowMember
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Measurement Input Extensible List
BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList
http://fasb.org/us-gaap/2021-01-31#MeasurementInputDiscountRateMember
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001372514
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3537175
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5067354
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124444363
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Valuation Technique Extensible List
BusinessCombinationContingentConsiderationLiabilityValuationTechniqueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueDiscountedCashFlowMember
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Measurement Input Extensible List
BusinessCombinationContingentConsiderationLiabilityMeasurementInputExtensibleList
http://fasb.org/us-gaap/2021-01-31#MeasurementInputDiscountRateMember
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50001
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36672
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
KIORA PHARMACEUTICALS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0443284
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1371 East 2100 South
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Salt Lake City
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84105
CY2022Q1 dei City Area Code
CityAreaCode
781
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
788-8869
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
KPRX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13067426
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5067354
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7854690
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
930345
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
606520
CY2022Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
552237
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
529560
CY2022Q1 us-gaap Assets Current
AssetsCurrent
6549936
CY2021Q4 us-gaap Assets Current
AssetsCurrent
8990770
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67297
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73999
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
45000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
45000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10761914
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10768164
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
158309
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
209411
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53820
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42964
CY2022Q1 us-gaap Assets
Assets
17636276
CY2021Q4 us-gaap Assets
Assets
20130308
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
302263
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
160621
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1832934
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1330141
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
92317
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
118846
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
293947
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
0
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2521461
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1609608
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
2988898
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3048955
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
802131
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
65992
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
802131
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90566
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3857021
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3941652
CY2022Q1 us-gaap Liabilities
Liabilities
6378482
CY2021Q4 us-gaap Liabilities
Liabilities
5551260
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12663965
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12663965
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
126640
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
126640
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135634109
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135418188
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124444363
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120879349
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58592
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-86431
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11257794
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14579048
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17636276
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20130308
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1664791
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1300143
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
707928
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1280242
CY2022Q1 us-gaap Severance Costs1
SeveranceCosts1
962833
CY2022Q1 kprx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
233890
CY2021Q1 kprx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-570203
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3569442
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
2010182
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3569442
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2010182
CY2022Q1 kprx Gain On Disposal Of Foreign Entity
GainOnDisposalOfForeignEntity
4211
CY2022Q1 kprx Interest Income
InterestIncome
217
CY2021Q1 kprx Interest Income
InterestIncome
250
CY2021Q1 us-gaap Interest Expense
InterestExpense
686
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4428
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-436
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3565014
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2010618
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13058629
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7357899
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3565014
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2010618
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
27839
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
10473
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2000145
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14579048
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
215921
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-27839
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3565014
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11257794
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9729741
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
216945
CY2021Q1 kprx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
50001
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
-10473
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2010618
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15985403
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3565014
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2010618
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10773
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10599
CY2022Q1 kprx Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
51102
CY2021Q1 kprx Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
39490
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
215921
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
216945
CY2022Q1 kprx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
233890
CY2021Q1 kprx Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-570203
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
4211
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
323825
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-216078
CY2022Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
33497
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
59706
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10856
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-8073
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
141641
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22583
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-51102
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-39490
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
502792
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-403802
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2832386
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2570051
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58119
CY2022Q1 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
6375
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6375
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-58119
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7988861
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50001
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8038862
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38675
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14123
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2787336
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5424815
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7899690
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1230677
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5112354
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6655492
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Business, Presentation and Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Kiora Pharmaceuticals, Inc. (“Kiora” or the “Company”) was formed as a Delaware corporation December 28, 2004 as amended. Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception, Kiora has devoted substantially all of its efforts to business planning, research and development, and raising capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The accompanying Condensed Consolidated Financial Statements have been prepared assuming that Kiora will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At March 31, 2022, Kiora had unrestricted Cash and Cash Equivalents of <span style="-sec-ix-hidden:Hidden_iEuSeP7Pb0mg3xqlHFTjtw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$5.067</span></span> million, and an Accumulated Deficit of <span style="-sec-ix-hidden:Hidden_g98cG72jmUO_DFYqfjDiOQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$124.444</span></span> million. Kiora has incurred losses and negative cash flows since inception, and future losses are anticipated. Based on its cash on hand at March 31, 2022, the Company anticipates having sufficient cash to fund planned operations through July 2022, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. To continue development, Kiora will need to raise additional capital through equity financing, license agreements, and/or additional U.S. government grants. Although historically the Company has been successful at raising capital, most recently raising net proceeds of approximately $9.756 million in a registered direct offering that closed on August 11, 2021, additional capital may not be available on terms favorable to Kiora, if at all. The Company does not know if any future offerings will succeed. Accordingly, no assurances can be given that Company management will succeed in these endeavors. The Company’s recurring losses from operations have caused management to determine there is substantial doubt about the Company’s ability to continue as a going concern. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unaudited Interim Financial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, they do not include all information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in the Company’s 2021 Annual Report on Form 10-K/A dated July 6, 2022. The balance sheet as of December 31, 2021 was derived from audited consolidated financial statements of the Company but does not include all the disclosures required by U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">None noted</p>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5067354
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7854690
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
45000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
45000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5112354
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7899690
CY2022Q1 kprx Accrued Executive Severance Current
AccruedExecutiveSeveranceCurrent
1049808
CY2021Q4 kprx Accrued Executive Severance Current
AccruedExecutiveSeveranceCurrent
200605
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
336680
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
737365
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
384452
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194425
CY2022Q1 kprx Clinical Trials Current
ClinicalTrialsCurrent
61994
CY2021Q4 kprx Clinical Trials Current
ClinicalTrialsCurrent
168785
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
28961
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1832934
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1330141
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
5290
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
1063000
CY2021Q4 kprx Goodwill Acquired
GoodwillAcquired
406599
CY2021Q4 kprx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities Accounts Payable And Other Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAccountsPayableAndOtherLiabilities
36525
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
265808
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
1172556
CY2022Q1 kprx Percentage Of Goodwill Representing Future Economic Benefits
PercentageOfGoodwillRepresentingFutureEconomicBenefits
1
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Measurement Input
BusinessCombinationContingentConsiderationLiabilityMeasurementInput
13.5
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Measurement Input
BusinessCombinationContingentConsiderationLiabilityMeasurementInput
13.1
CY2022Q1 kprx Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
234000
CY2021Q1 kprx Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
-507000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1531101
CY2021Q1 kprx Class Of Warrant Or Right Number Of Warrant Issued
ClassOfWarrantOrRightNumberOfWarrantIssued
1531101
CY2021Q1 kprx Share Purchase Price Of Common Stock And Warrant
SharePurchasePriceOfCommonStockAndWarrant
5.225
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8000000.000
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7162730
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6757180
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6757180
CY2022Q1 kprx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
4.99
CY2021Q4 kprx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice
4.99
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y5M1D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y5M1D
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0
CY2022Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
8797
CY2021Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
54709
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7437419
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5483243
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
215921
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
216945
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0242
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.40
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.68
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
647000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
515922
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.43
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
260500
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.76
CY2022Q1 kprx Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y10M2D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
12662
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.87
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
85610
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.79
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
678150
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.85
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
241683
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
18.57
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P2Y3M18D
CY2022Q1 us-gaap Share Price
SharePrice
0.62
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
55000.000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
51000.000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
55779
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
55738
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0466
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0532
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2020Q2 kprx Payment Of Annual Fee
PaymentOfAnnualFee
5000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
18799451
CY2022Q1 us-gaap Contingent Consideration Classified As Equity Fair Value Disclosure
ContingentConsiderationClassifiedAsEquityFairValueDisclosure
3282845
CY2022Q1 us-gaap Area Of Land
AreaOfLand
1100
CY2022Q1 us-gaap Increase Decrease In Lease Acquisition Costs
IncreaseDecreaseInLeaseAcquisitionCosts
38700
CY2022Q2 us-gaap Increase Decrease In Lease Acquisition Costs
IncreaseDecreaseInLeaseAcquisitionCosts
25000

Files In Submission

Name View Source Status
0001410578-22-001934-index-headers.html Edgar Link pending
0001410578-22-001934-index.html Edgar Link pending
0001410578-22-001934.txt Edgar Link pending
0001410578-22-001934-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kprx-20220331.xsd Edgar Link pending
kprx-20220331x10q.htm Edgar Link pending
kprx-20220331x10q_htm.xml Edgar Link completed
kprx-20220331xex31d1.htm Edgar Link pending
kprx-20220331xex32d1.htm Edgar Link pending
kprx-20220331_cal.xml Edgar Link unprocessable
kprx-20220331_def.xml Edgar Link unprocessable
kprx-20220331_lab.xml Edgar Link unprocessable
kprx-20220331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending